Differential effects of methoxyamine on doxorubicin cytotoxicity and genotoxicity in MDA-MB-231 human breast cancer cells

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 757, Issue 2, 2013, Pages 140-147

  Guerreiro, Patrícia S ^a   Fernandes, Ana Sofia ^a,b   Costa, João G ^a,b   Castro, Matilde ^a   Miranda, Joana P ^a   Oliveira, Nuno G ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSIDADE LUSÓFONA DE HUMANIDADES E TECNOLOGIAS   (Portugal)

Author keywords

APE1; Base excision repair; DNA repair; Doxorubicin; Methoxyamine; Micronuclei

Indexed keywords

DOXORUBICIN; HYDROETHIDINE; METHOXYAMINE; REACTIVE OXYGEN METABOLITE;

ARTICLE; BREAST METASTASIS; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINESIS; CYTOTOXICITY; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE; GENOTOXICITY; HUMAN; HUMAN CELL; MICRONUCLEUS TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

APE1; BASE EXCISION REPAIR; DNA REPAIR; DOXORUBICIN; METHOXYAMINE; MICRONUCLEI;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOKINESIS; CYTOTOXINS; DNA DAMAGE; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; HYDROXYLAMINES; MICRONUCLEI, CHROMOSOME-DEFECTIVE; NEOPLASM PROTEINS;

EID: 84885858884     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2013.08.003     Document Type: Article

References (69)

1. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8:193-204.
2. Rodrigues A.S., Gomes B.C., Martins C., Gromicho M., Oliveira N.G., Guerreiro P.S., et al. DNA repair and resistance to cancer therapy. New Research Directions in DNA Repair 2013, 489-528. InTech, Rijeka. C. Chen (Ed.).
3. Izumi T., Wiederhold L.R., Roy G., Roy R., Jaiswal A., Bhakat K.K., et al. Mammalian DNA base excision repair proteins: their interactions and role in repair of oxidative DNA damage. Toxicology 2003, 193:43-65.
4. Hegde M.L., Hazra T.K., Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 2008, 18:27-47.
5. Bapat A., Fishel M.L., Kelley M.R. Going ape as an approach to cancer therapeutics. Antioxid. Redox Signal. 2009, 11:651-667.
6. Das A., Wiederhold L., Leppard J.B., Kedar P., Prasad R., Wang H., et al. NEIL2-initiated, APE-independent repair of oxidized bases in DNA: evidence for a repair complex in human cells. DNA Repair 2006, 5:1439-1448.
7. Masani S., Han L., Yu K. Apurinic/apyrimidinic endonuclease 1 is the essential nuclease during immunoglobulin class switch recombination. Mol. Cell. Biol. 2013, 33:1468-1473.
8. Kakolyris S., Kaklamanis L., Engels K., Fox S.B., Taylor M., Hickson I.D., et al. Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. Br. J. Cancer 1998, 77:1169-1173.
9. Kakolyris S., Kaklamanis L., Engels K., Turley H., Hickson I.D., Gatter K.C., et al. Human apurinic endonuclease 1 expression in a colorectal adenoma-carcinoma sequence. Cancer Res. 1997, 57:1794-1797.
10. Di Maso V., Avellini C., Crocè L.S., Rosso N., Quadrifoglio F., Cesaratto L., et al. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol. Med. 2007, 13:89-96.
11. Moore D.H., Michael H., Tritt R., Parsons S.H., Kelley M.R. Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin. Cancer Res. 2000, 6:602-609.
12. Puglisi F., Aprile G., Minisini A.M., Barbone F., Cataldi P., Tells G., et al. Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas. Anticancer Res. 2001, 21:4041-4049.
13. Liuzzi M., Talpaert-Borle M. A new approach to the study of the base-excision repair pathway using methoxyamine. J. Biol. Chem. 1985, 260:5252-5258.
14. Fortini P., Calcagnile A., Vrieling H., van Zeeland A.A., Bignami M., Dogliotti E. Mutagenic processing of ethylation damage in mammalian cells: the use of methoxyamine to study apurinic/apyrimidinic site-induced mutagenesis. Cancer Res. 1993, 53:1149-1155.
15. Yan L., Bulgar A., Miao Y., Mahajan V., Donze J.R., Gerson S.L., et al. Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIα. Clin. Cancer Res. 2007, 13:1532-1539.
16. Taverna P., Liu L., Hwang H.-S., Hanson A.J., Kinsella T.J., Gerson S.L. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat. Res. 2001, 485:269-281.
17. Fishel M.L., He Y., Smith M.L., Kelley M.R. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin. Cancer Res. 2007, 13:260-267.
18. Liu L., Yan L., Donze J.R., Gerson S.L. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Mol. Cancer Ther. 2003, 2:1061-1066.
19. Bulgar A.D., Weeks L.D., Miao Y., Yang S., Xu Y., Guo C., et al. Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. Cell Death Dis. 2012, 3:e252.
20. Taverna P., Hwang H.-S., Schupp J.E., Radivoyevitch T., Session N.N., Reddy G., et al. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Cancer Res. 2003, 63:838-846.
21. Yan T., Seo Y., Schupp J.E., Zeng X., Desai A.B., Kinsella T.J. Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol. Cancer Ther. 2006, 5:893-902.
22. Savvides P.S., Xu Y., Liu L., Rogers L., Bokar J., Silverman P., et al. Phase 1 clinical trial of the base-excision repair inhibitor methoxyamine-HCl (TRC102; MX) in combination with temozolomide (TMZ) in patients with solid tumors. Cancer Res. 2012, 72(8 Suppl.). [abstract no. 1743].
23. Savvides P.S., Xu Y., Liu L., Rogers L., Krishnamurthi S., Dowlati A., et al. Pharmacokinetic profile of the base-excision repair inhibitor methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous infusion with temozolomide (TMZ) in the first in human phase 1 clinical trial. Cancer Res. 2012, 72(8 Suppl.). [abstract no. 753].
24. Gordon M.S., Rosen L.S., Mendelson D., Ramanathan R.K., Goldman J., Liu L., et al. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest. New Drugs 2013, 31:714-723.
25. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
26. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
27. Müller I., Jenner A., Bruchelt G., Niethammer D., Halliwell B. Effect of concentration on the cytotoxic mechanism of doxorubicin - apoptosis and oxidative DNA damage. Biochem. Biophys. Res. Commun. 1997, 230:254-257.
28. Spencer D.M.S., Bilardi R.A., Koch T.H., Post G.C., Nafie J.W., Kimura K.-I., et al. DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair. Mutat. Res. 2008, 638:110-121.
29. Saffi J., Agnoletto M.H., Guecheva T.N., Batista L.F.Z., Carvalho H., Henriques J.A.P., et al. Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells. DNA Repair 2010, 9:40-47.
30. Davidson D., Grenier J., Martinez-Marignac V., Amrein L., Shawi M., Tokars M., et al. Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. Invest. New Drugs 2012, 30:1736-1742.
31. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
32. Fernandes A.S., Serejo J., Gaspar J., Cabral F., Bettencourt A.F., Rueff J., et al. Oxidative injury in V79 Chinese hamster cells: protective role of the superoxide dismutase mimetic MnTM-4-PyP. Cell Biol. Toxicol. 2010, 26:91-101.
33. Fernandes A.S., Gaspar J., Cabral M.F., Rueff J., Castro M., Batinic-Haberle I., et al. Protective role of ortho-substituted Mn(III) N-alkylpyridylporphyrins against the oxidative injury induced by tert-butylhydroperoxide. Free Radic. Res. 2010, 44:430-440.
34. Franken N.A.P., Rodermond H.M., Stap J., Haveman J., van Bree C. Clonogenic assay of cells in vitro. Nat. Protoc. 2006, 1:2315-2319.
35. Gonçalves S., Fernandes A.S., Oliveira N.G., Marques J., Costa J., Cabral M.F., et al. Cytotoxic effects of cadmium in mammary epithelial cells: protective role of the macrocycle [15]pyN5. Food Chem. Toxicol. 2012, 50:2180-2187.
36. Fenech M. Cytokinesis-block micronucleus cytome assay. Nat. Protoc. 2007, 2:1084-1104.
37. Ramos D.L., Gaspar J.F., Pingarilho M., Gil O.M., Fernandes A.S., Rueff J., et al. Genotoxic effects of doxorubicin in cultured human lymphocytes with different glutathione S-transferase genotypes. Mutat. Res. 2011, 724:28-34.
38. Oliveira N.G., Castro M., Rodrigues A.S., Gonçalves I.C., Cassapo R., Fernandes A.P., et al. Evaluation of the genotoxic effects of the boron neutron capture reaction in human melanoma cells using the cytokinesis block micronucleus assay. Mutagenesis 2001, 16:369-375.
39. Fenech M. The in vitro micronucleus technique. Mutat. Res. 2000, 455:81-95.
40. Henle E.S., Linn S. Formation, prevention, and repair of DNA damage by iron/hydrogen peroxide. J. Biol. Chem. 1997, 272:19095-19098.
41. Termini J. Hydroperoxide-induced DNA damage and mutations. Mutat. Res. 2000, 450:107-124.
42. Jiang Y., Guo C., Fishel M.L., Wang Z.-Y., Vasko M.R., Kelley M.R. Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair 2009, 8:1273-1282.
43. Shimizu N., Sugimoto K., Tang J., Nishi T., Sato I., Hiramoto M., et al. High-performance affinity beads for identifying drug receptors. Nat. Biotechnol. 2000, 18:877-881.
44. Zou G.M., Luo M.H., Reed A., Kelley M.R., Yoder M.C. Ape1 regulates hematopoietic differentiation of embryonic stem cells through its redox functional domain. Blood 2007, 109:1917-1922.
45. Zou G.M., Maitra A. Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol. Cancer Ther. 2008, 7:2012-2021.
46. Manvilla B.A., Wauchope O., Seley-Radtke K.L., Drohat A.C. NMR studies reveal an unexpected binding site for a redox inhibitor of AP endonuclease 1. Biochemistry 2011, 50:10540-10549.
47. Zhang J., Luo M., Marasco D., Logsdon D., LaFavers K.A., Chen Q., et al. Inhibition of apurinic/apyrimidinic endonuclease I's redox activity revisited. Biochemistry 2013, 52:2955-2966.
48. Maggiorella L., Deutsch E., Frascogna V., Chavaudra N., Jeanson L., Milliat F., et al. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Cancer Res. 2003, 63:2513-2517.
49. Yoon D.-S., Wersto R.P., Zhou W., Chrest F.J., Garrett E.S., Kwon T.K., et al. Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am. J. Pathol. 2002, 161:391-397.
50. Capranico G., De Isabella P., Penco S., Tinelli S., Zunino F. Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells. Cancer Res. 1989, 49:2022-2027.
51. Doroshow J.H., Synold T.W., Somlo G., Akman S.A., Gajewski E. Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 2001, 97:2839-2845.
52. Gajewski E., Gaur S., Akman S.A., Matsumoto L., van Balgooy J.N.A., Doroshow J.H. Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin. Biochem. Pharmacol. 2007, 73:1947-1956.
53. Minisini A.M., Di Loreto C., Mansutti M., Artico D., Pizzolitto S., Piga A., et al. Topoisomerase IIα and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett. 2005, 224:133-139.
54. Azzariti A., Bocci G., Porcelli L., Fioravanti A., Sini P., Simone G.M., et al. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br. J. Cancer 2011, 104:769-780.
55. Mansilla S., Priebe W., Portugal J. Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle 2006, 5:53-60.
56. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999, 59:1391-1399.
57. van Wijngaarden J., van Beek E., van Rossum G., van der Bent C., Hoekman K., van der Pluijm G., et al. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-κB-mediated increase of intracellular doxorubicin accumulation. Eur. J. Cancer 2007, 43:433-442.
58. Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 2013, 65:157-170.
59. Xu D., Shiu R.P., Newsham I.F., Gewirtz D.A. Apoptosis, autophagy, accelerated senescence and reactive oxygen in the response of human breast tumor cells to adriamycin. Biochem. Pharmacol. 2009, 77:1139-1150.
60. Sliwinska M.A., Mosieniak G., Wolanin K., Babik A., Piwocka K., Magalska A., et al. Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells. Mech. Ageing Dev. 2009, 130:24-32.
61. Madhusudan S., Smart F., Shrimpton P., Parsons J.L., Gardiner L., Houlbrook S., et al. Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res. 2005, 33:4711-4724.
62. Mohammed M.Z., Vyjayanti V.N., Laughton C.A., Dekker L.V., Fischer P.M., Wilson D.M., et al. Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br. J. Cancer 2011, 104:653-663.
63. Koedrith P., Seo Y.R. Sensitizing effect of silencing Ape1/Ref-1 on doxorubicin-induced apoptosis in human carcinoma cells. Mol. Cell Toxicol. 2012, 7:389-397.
64. Zhou S., Palmeira C.M., Wallace K.B. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol. Lett. 2001, 121:151-157.
65. Bernuzzi F., Recalcati S., Alberghini A., Cairo G. Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation. Chem. Biol. Interact. 2009, 177:12-20.
66. Wandl E.O., Ono K., Kain R., Herbsthofer T., Hienert G., Höbarth K. Linear correlation between surviving fraction and the micronucleus frequency. Int. J. Radiat. Biol. 1989, 56:771-775.
67. Jagetia G.C., Nayak V. Micronuclei-induction and its correlation to cell survival in HeLa cells treated with different doses of adriamycin. Cancer Lett. 1996, 110:123-128.
68. Champion A.R., Hanson J.A., Court J.B., Venables S.E. The micronucleus assay: an evaluation of its use in determining radiosensitivity in vitro. Mutagenesis 1995, 10:203-208.
69. Villa R., Zaffaroni N., Gornati D., Costa A., Silvestrini R. Lack of a correlation between micronucleus formation and radiosensitivity in established and primary cultures of human tumours. Br. J. Cancer 1994, 70:1112-1117.